Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis

Overview

Journal Contrast Media Mol Imaging

Specialty Radiology

Date 2021 Sep 22

PMID 34548851

Citations 3

Authors

Yu Wang

Yanfeng Xu

Ying Kan

Wei Wang

Jigang Yang

Affiliations

Soon will be listed here.

Abstract

Objective: We performed a systematic review and network meta-analysis (NMA) to compare the diagnostic value of seven different imaging modalities for the detection of neuroblastic tumors in diverse clinical settings.

Methods: PubMed, Embase, Medline, and the Cochrane Library were searched to identify eligible studies from inception to Sep 29, 2020. Quality assessment of included studies was appraised with Quality Assessment of Diagnostic Accuracy Studies. Firstly, direct pairwise meta-analysis was conducted to calculate the pooled estimates of odds ratio (OR) and 95% confidence interval (CI) of the sensitivity, specificity, NPV, PPV, and DR. Next, NMA using Bayesian methods was performed. The superiority index was assessed to quantify the rank probability of a diagnostic test. The studies performed SPECT/CT or SPECT were analyzed separately from the ones only performed planar imaging.

Results: A total of 1135 patients from 32 studies, including 7 different imaging modalities, were eligible for this NMA. In the pairwise meta-analysis, F-FDOPA PET/CT had a relatively high value of all the outcomes (sensitivity: 10.195 [5.332-19.493]; specificity: 17.906 [5.950-53.884]; NPV: 16.819 [7.033-40.218]; PPV: 11.154 [4.216-29.512]; and DR 5.616 [3.609-8.739]). In the NMA, F-FDOPA PET/CT exhibited relatively high sensitivity in all subgroups (all data: 0.94 [0.87-0.98]; primary tumor: 0.89 [0.53-1]; bone/bone marrow metastases: 0.96 [0.83-1]; and primary tumor and metastases ( + ): 0.92 [0.80-0.97]), the highest specificity in the subgroup of + (0.85 [0.61-0.97]), and achieved the highest superiority index in the subgroups of all data (8.57 [1-15]) and + (7.25 [1-13]).

Conclusion: F-FDOPA PET/CT exhibited the best diagnostic performance in the comprehensive detection of primary tumor and metastases for neuroblastic tumors, followed by Ga-somatostatin analogs, I-meta-iodobenzylguanidine (MIBG), F-FDG, and I-MIBG tomographic imaging.

Citing Articles

Clinical value of F-FDG PET/CT to predict MYCN gene, chromosome 1p36 and 11q status in pediatric neuroblastoma and ganglioneuroblastoma.

Ren J, Fu Z, Zhao Y Front Oncol. 2023; 13:1099290.

PMID: 37035169 PMC: 10079884. DOI: 10.3389/fonc.2023.1099290.

Comparing the diagnostic value of 18F-FDG PET/CT scan and bone marrow biopsy in newly diagnosed pediatric neuroblastoma and ganglioneuroblastoma.

Fu Z, Ren J, Zhou J, Shen J Front Oncol. 2023; 12:1031078.

PMID: 36591533 PMC: 9798316. DOI: 10.3389/fonc.2022.1031078.

Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patient's Favor.

Pacak K, Taieb D, Jha A J Clin Endocrinol Metab. 2022; 107(9):e3953-e3954.

PMID: 35536703 PMC: 9387716. DOI: 10.1210/clinem/dgac298.

References

Sarioglu F, Salman M, Guleryuz H, Ozer E, Cecen E, Ince D . Radiological staging in neuroblastoma: computed tomography or magnetic resonance imaging?. Pol J Radiol. 2019; 84:e46-e53. PMC: 6479053. DOI: 10.5114/pjr.2019.82736. View

Melzer H, Coppenrath E, Schmid I, Albert M, von Schweinitz D, Tudball C . ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011; 38(9):1648-58. DOI: 10.1007/s00259-011-1843-8. View

Choi Y, Hwang H, Kim H, Jeong Y, Cho A, Lee J . (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. Ann Nucl Med. 2014; 28(4):304-13. DOI: 10.1007/s12149-014-0813-1. View

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman M, Lopci E . Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018; 45(11):2009-2024. DOI: 10.1007/s00259-018-4070-8. View

Zhang H, Huang R, Cheung N, Guo H, Zanzonico P, Thaler H . Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014; 20(8):2182-91. PMC: 4072734. DOI: 10.1158/1078-0432.CCR-13-1153. View

Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W . Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011; 38(5):865-73. DOI: 10.1007/s00259-010-1720-x. View

Piccardo A, Morana G, Puntoni M, Campora S, Sorrentino S, Zucchetta P . Diagnosis, Treatment Response, and Prognosis: The Role of F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with I-mIBG Scan: The First Prospective Study. J Nucl Med. 2019; 61(3):367-374. DOI: 10.2967/jnumed.119.232553. View

Shahrokhi P, Emami-Ardekani A, Harsini S, Eftekhari M, Fard-Esfahani A, Fallahi B . Ga-DOTATATE PET/CT Compared with I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors. Asia Ocean J Nucl Med Biol. 2020; 8(1):8-17. PMC: 6994775. DOI: 10.22038/aojnmb.2019.41343.1280. View

Lastoria S, Maurea S, Caraco C, Vergara E, Maurelli L, Indolfi P . Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography. Eur J Nucl Med. 1993; 20(12):1161-7. DOI: 10.1007/BF00171014. View

10.

Kundu S, Kand P, Basu S . Comparative evaluation of iodine-131 metaiodobenzylguanidine and 18-fluorodeoxyglucose positron emission tomography in assessing neural crest tumors: Will they play a complementary role?. South Asian J Cancer. 2017; 6(1):31-34. PMC: 5379891. DOI: 10.4103/2278-330X.202556. View

11.

Nyaga V, Aerts M, Arbyn M . ANOVA model for network meta-analysis of diagnostic test accuracy data. Stat Methods Med Res. 2016; 27(6):1766-1784. DOI: 10.1177/0962280216669182. View

12.

Li C, Zhang J, Chen S, Huang S, Wu S, Zhang L . Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma. Eur J Nucl Med Mol Imaging. 2017; 45(2):306-315. DOI: 10.1007/s00259-017-3851-9. View

13.

Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E . 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003; 30(5):689-94. DOI: 10.1007/s00259-003-1115-3. View

14.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

15.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I . Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002; 222(2):507-12. DOI: 10.1148/radiol.2222010622. View

16.

Liu B, Zhuang H, Servaes S . Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors. Q J Nucl Med Mol Imaging. 2013; 57(1):21-8. View

17.

Ishiguchi H, Ito S, Kato K, Sakurai Y, Kawai H, Fujita N . Diagnostic performance of F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma. Ann Nucl Med. 2018; 32(5):348-362. PMC: 5970256. DOI: 10.1007/s12149-018-1254-z. View

18.

Abrahamsen J, Lyck B, Helgestad J, Frederiksen P . The impact of 123I-meta-iodobenzylguanidine scintigraphy on diagnostics and follow-up of neuroblastoma. Acta Oncol. 1995; 34(4):505-10. DOI: 10.3109/02841869509094015. View

19.

Matthay K, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V . Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003; 98(1):155-65. DOI: 10.1002/cncr.11448. View

20.

Sharp S, Shulkin B, Gelfand M, Salisbury S, Furman W . 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237-43. DOI: 10.2967/jnumed.108.060467. View